Drug intelligence / Profile preview

LY4005130

Development stage: Phase 2
Lead developer: Eli Lilly
Administration: Subcutaneous, Intravenous

Overview

LY4005130 is an investigational drug developed by Eli Lilly and Company. It is currently in Phase 1 clinical trials to evaluate its safety, tolerability, and pharmacokinetics in healthy participants. The drug is being administered either subcutaneously or intravenously. As of now, the specific mechanism of action and therapeutic indication for LY4005130 have not been disclosed publicly[1][2][3][4]. The compound is classified as a new molecular entity.

Other names: LY-4005130LY4005130LY 4005130

Beyond the preview

Go deeper on LY4005130.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY4005130.

Explore the full profile